Gerontechnology Evaluation Framework: Outcome Validation

November 24, 2023 updated by: Dr. Derek Yee-Tak Cheung, The University of Hong Kong
The project aims to validate the evaluation indicators applicability of 9 Gerontechnology Evaluation Frameworks. The outcome is the perceived importance of the evaluation indicators described in the 9 Evaluation Frameworks. Participants will be invited to complete a questionnaire indicating the importance of the outcomes.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Not yet recruiting

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

This study is a cross-sectional survey. 165 to 300 participants will be recruited to complete a questionnaire. For each product theme that they are familiar with, they will rate anonymously the perceived importance of the evaluation indicators on a 5-point Likert scale, give reasons for their ratings and suggest revisions.

Participants will be recruited through convenience sampling in 3 subgroups, including (1) members of Gerontechnology Application and Testing Working Group under Gerontechnology Platform, (2) successful applicants of Innovation and Technology Fund for buying gerontechnology products under the 9 themes, and (3) visitors of Gerontech and Innovation Expo. It is expected that 35% participants will be recruited in subgroup 1, 5% in subgroup 2, and 60% in subgroup 3.

Gerontechnology Platform will invite (1) its members of Gerontechnology Application and Testing Working Group, who are the Users, Caregivers, Staff and Suppliers of gerontechnology products, to fill in the questionnaire online. 3 email reminders will be sent to remind them to complete the questionnaire. (2) The list of successful applicants of Innovation and Technology Fund who applied for the product themes covered in the 9 Evaluation Frameworks will be downloaded from the Social Welfare Department website and their Staff will be invited to fill in the questionnaire online. (3) In Gerontech and Innovation Expo, which is a local exhibition that provides a platform for stakeholders to discuss and collaborate for broader adoption of gerontechnology, research staff will approach all visitors of the Gerontechnology Platform booth. The visitors who fulfil the inclusion and exclusion criteria will be invited to complete the questionnaire.

To ensure the validity of their responses, they will only answer the questionnaire items of the themes they have known, have used, or are most interested. For each product theme that they are familiar with, they will rate anonymously the perceived importance of the evaluation indicators on a 5-point Likert scale, give reasons for their ratings and suggest revisions. Their voluntary written consent will be sought before they complete the questionnaire. Each questionnaire will take around 5 - 10 minutes.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Observational

Enrollment (Estimated)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
300

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact

The name and contact information for the person who can answer enrollment questions for a clinical study. Each location where the study is being conducted may also have a specific contact, who may be better able to answer those questions.

Study Locations

  • Hong Kong
      • Hong Kong, Hong Kong
        • The University of Hong Kong

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Sampling Method

Non-Probability Sample

Study Population

Stakeholders of gerontechnology in Hong Kong

Description

Inclusion Criteria:

  • People in one of these categories: Working or has worked in a social service setting for the elderly or person with disability (Staff), an elderly aged 60 or above (User), a person with physical or disability (User), an informal caregiver for an elderly or a person with disability (Caregiver), or belonging to a company/or that has developed or retailed gerontechnology products (Supplier)

Exclusion Criteria:

  • Unable to read or write in Chinese

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort

Group / Cohort

A group or subgroup of participants in an observational study that is assessed for biomedical or health outcomes.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Staff
A cross-sectional survey will be conducted.
Other: Doing questionnaire
Participants will provide their opinions in a questionnaire
User
A cross-sectional survey will be conducted.
Other: Doing questionnaire
Participants will provide their opinions in a questionnaire
Caregiver
A cross-sectional survey will be conducted.
Other: Doing questionnaire
Participants will provide their opinions in a questionnaire
Supplier
A cross-sectional survey will be conducted.
Other: Doing questionnaire
Participants will provide their opinions in a questionnaire

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Degree of importance on indicators of fall prevention Framework
Time Frame: 3 months
The level of agreement on indicators of fall prevention Framework. The opinions will be categorized into four levels of consensus according to the central tendency, level of dispersion, and the rated level of importance (Shi et al., 2022). The consensus levels are defined as: very high consensus (median = 5, inter-quartile range (IQR) = 0, rating score of 4/5 ≥ 80%); high consensus (median = 5, IQR = 1, rating score of 4/5 ≥ 80%); moderate consensus (median = 4-5, IQR = 1, rating score 4/5 ≥ 75%), and low consensus (median ≤ 4, IQR ≤ 2, rating score 4/5 < 75%).
3 months
Degree of importance on indicators of health monitoring Framework
Time Frame: 3 months
The level of agreement on indicators of health monitoring Framework. The opinions will be categorized into four levels of consensus according to the central tendency, level of dispersion, and the rated level of importance (Shi et al., 2022). The consensus levels are defined as: very high consensus (median = 5, inter-quartile range (IQR) = 0, rating score of 4/5 ≥ 80%); high consensus (median = 5, IQR = 1, rating score of 4/5 ≥ 80%); moderate consensus (median = 4-5, IQR = 1, rating score 4/5 ≥ 75%), and low consensus (median ≤ 4, IQR ≤ 2, rating score 4/5 < 75%).
3 months
Degree of importance on indicators of transfer and lifting Framework
Time Frame: 3 months
The level of agreement on indicators of transfer and lifting Framework. The opinions will be categorized into four levels of consensus according to the central tendency, level of dispersion, and the rated level of importance (Shi et al., 2022). The consensus levels are defined as: very high consensus (median = 5, inter-quartile range (IQR) = 0, rating score of 4/5 ≥ 80%); high consensus (median = 5, IQR = 1, rating score of 4/5 ≥ 80%); moderate consensus (median = 4-5, IQR = 1, rating score 4/5 ≥ 75%), and low consensus (median ≤ 4, IQR ≤ 2, rating score 4/5 < 75%).
3 months
Degree of importance on indicators of hygiene management Framework
Time Frame: 3 months
The level of agreement on indicators of hygiene management Framework. The opinions will be categorized into four levels of consensus according to the central tendency, level of dispersion, and the rated level of importance (Shi et al., 2022). The consensus levels are defined as: very high consensus (median = 5, inter-quartile range (IQR) = 0, rating score of 4/5 ≥ 80%); high consensus (median = 5, IQR = 1, rating score of 4/5 ≥ 80%); moderate consensus (median = 4-5, IQR = 1, rating score 4/5 ≥ 75%), and low consensus (median ≤ 4, IQR ≤ 2, rating score 4/5 < 75%).
3 months
Degree of importance on indicators of communication Framework
Time Frame: 3 months
The level of agreement on indicators of communication Framework. The opinions will be categorized into four levels of consensus according to the central tendency, level of dispersion, and the rated level of importance (Shi et al., 2022). The consensus levels are defined as: very high consensus (median = 5, inter-quartile range (IQR) = 0, rating score of 4/5 ≥ 80%); high consensus (median = 5, IQR = 1, rating score of 4/5 ≥ 80%); moderate consensus (median = 4-5, IQR = 1, rating score 4/5 ≥ 75%), and low consensus (median ≤ 4, IQR ≤ 2, rating score 4/5 < 75%).
3 months
Degree of importance on indicators of anti-wandering Framework
Time Frame: 3 months
The level of agreement on indicators of anti-wandering Framework. The opinions will be categorized into four levels of consensus according to the central tendency, level of dispersion, and the rated level of importance (Shi et al., 2022). The consensus levels are defined as: very high consensus (median = 5, inter-quartile range (IQR) = 0, rating score of 4/5 ≥ 80%); high consensus (median = 5, IQR = 1, rating score of 4/5 ≥ 80%); moderate consensus (median = 4-5, IQR = 1, rating score 4/5 ≥ 75%), and low consensus (median ≤ 4, IQR ≤ 2, rating score 4/5 < 75%).
3 months
Degree of importance on indicators of air quality sensor Framework
Time Frame: 3 months
The level of agreement on indicators of air quality sensor Framework. The opinions will be categorized into four levels of consensus according to the central tendency, level of dispersion, and the rated level of importance (Shi et al., 2022). The consensus levels are defined as: very high consensus (median = 5, inter-quartile range (IQR) = 0, rating score of 4/5 ≥ 80%); high consensus (median = 5, IQR = 1, rating score of 4/5 ≥ 80%); moderate consensus (median = 4-5, IQR = 1, rating score 4/5 ≥ 75%), and low consensus (median ≤ 4, IQR ≤ 2, rating score 4/5 < 75%).
3 months
Degree of importance on indicators of feeding tools Framework
Time Frame: 3 months
The level of agreement on indicators of feeding tools Framework. The opinions will be categorized into four levels of consensus according to the central tendency, level of dispersion, and the rated level of importance (Shi et al., 2022). The consensus levels are defined as: very high consensus (median = 5, inter-quartile range (IQR) = 0, rating score of 4/5 ≥ 80%); high consensus (median = 5, IQR = 1, rating score of 4/5 ≥ 80%); moderate consensus (median = 4-5, IQR = 1, rating score 4/5 ≥ 75%), and low consensus (median ≤ 4, IQR ≤ 2, rating score 4/5 < 75%).
3 months
Degree of importance on indicators of cognitive training and stimulation Framework
Time Frame: 3 months
The level of agreement on indicators of cognitive training and stimulation Framework. The opinions will be categorized into four levels of consensus according to the central tendency, level of dispersion, and the rated level of importance (Shi et al., 2022). The consensus levels are defined as: very high consensus (median = 5, inter-quartile range (IQR) = 0, rating score of 4/5 ≥ 80%); high consensus (median = 5, IQR = 1, rating score of 4/5 ≥ 80%); moderate consensus (median = 4-5, IQR = 1, rating score 4/5 ≥ 75%), and low consensus (median ≤ 4, IQR ≤ 2, rating score 4/5 < 75%).
3 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
The University of Hong Kong

Collaborators

Collaborators

An organization other than the sponsor that provides support for a clinical study. This support may include activities related to funding, design, implementation, data analysis, or reporting.
Gerontechnology Platform, The Social Innovation and Entrepreneurship Development Fund

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
November 1, 2023

Primary Completion (Estimated)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
January 1, 2024

Study Completion (Estimated)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
June 1, 2024

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
November 17, 2023

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
November 17, 2023

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
November 27, 2023

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
November 29, 2023

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
November 24, 2023

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
November 1, 2023

More Information

Terms related to this study

Keywords

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • Gerontechnology Outcome

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

Individual participant data (IPD) will not be available

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings